Form 483

Huvepharma, Inc. Form 483, 2011-06-16

FDA issued a Form 483 to Huvepharma, Inc. on 2011-06-16 with 9 public-safe observations.

483· Form 483 issued9 observations

Huvepharma, Inc. · Saint Louis, United States · Issued June 16, 2011

Overview

  • 9 public-safe observations are available for this inspection.
  • 9 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

16 Jun 2011
21 CFR 211.25(a)

Training , Education , Experience overall

Cited by Shafiq Ahadi, Sherry G Bous, Adree N Anderson

16 Jun 2011
21 CFR 211.42(c)(2)

Rejected Material Area

Cited by Shafiq Ahadi, Sherry G Bous, Adree N Anderson

16 Jun 2011
21 CFR 211.42(c)(7)

Quarantined Drug Products Area

Cited by Shafiq Ahadi, Sherry G Bous, Adree N Anderson

16 Jun 2011
21 CFR 211.67(b)

Written procedures fail to include

Cited by Shafiq Ahadi, Sherry G Bous, Adree N Anderson

16 Jun 2011
21 CFR 211.125(a)

Strict control not exercised over labeling issued

Cited by Shafiq Ahadi, Sherry G Bous, Adree N Anderson

Inspected site

HIHuvepharma, Inc.Saint Louis, United States

Inspection team

ANAdree N Anderson

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.125(a)Cited across public-safe Form 483 observations1x
21 CFR 211.142Cited across public-safe Form 483 observations1x
21 CFR 211.142(b)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(7)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 9 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere